A citation-based method for searching scientific literature

Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina Vaccaro, Davide Melisi, Raed Al-Rajabi, Andrew S Paulson, Mitesh J Borad, David Gallinson, Adrian G Murphy, Do-Youn Oh, Efrat Dotan, Daniel V Catenacci, Eric Van Cutsem, Tao Ji, Christine F Lihou, Huiling Zhen, Luis Féliz, Arndt Vogel. Lancet Oncol 2020
Times Cited: 361







List of co-cited articles
739 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Juan Valle, Harpreet Wasan, Daniel H Palmer, David Cunningham, Alan Anthoney, Anthony Maraveyas, Srinivasan Madhusudan, Tim Iveson, Sharon Hughes, Stephen P Pereira,[...]. N Engl J Med 2010
57

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Ghassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, Robin K Kelley, Sam J Lubner, Jorge Adeva, James M Cleary, Daniel V Catenacci, Mitesh J Borad, John Bridgewater,[...]. Lancet Oncol 2020
236
45

Cholangiocarcinoma 2020: the next horizon in mechanisms and management.
Jesus M Banales, Jose J G Marin, Angela Lamarca, Pedro M Rodrigues, Shahid A Khan, Lewis R Roberts, Vincenzo Cardinale, Guido Carpino, Jesper B Andersen, Chiara Braconi,[...]. Nat Rev Gastroenterol Hepatol 2020
352
34

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
Milind Javle, Maeve Lowery, Rachna T Shroff, Karl Heinz Weiss, Christoph Springfeld, Mitesh J Borad, Ramesh K Ramanathan, Lipika Goyal, Saeed Sadeghi, Teresa Macarulla,[...]. J Clin Oncol 2018
302
31

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.
Angela Lamarca, Daniel H Palmer, Harpreet Singh Wasan, Paul J Ross, Yuk Ting Ma, Arvind Arora, Stephen Falk, Roopinder Gillmore, Jonathan Wadsley, Kinnari Patel,[...]. Lancet Oncol 2021
91
30

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.
Vincenzo Mazzaferro, Bassel F El-Rayes, Michele Droz Dit Busset, Christian Cotsoglou, William P Harris, Nevena Damjanov, Gianluca Masi, Lorenza Rimassa, Nicola Personeni, Fadi Braiteh,[...]. Br J Cancer 2019
146
27

Genomic spectra of biliary tract cancer.
Hiromi Nakamura, Yasuhito Arai, Yasushi Totoki, Tomoki Shirota, Asmaa Elzawahry, Mamoru Kato, Natsuko Hama, Fumie Hosoda, Tomoko Urushidate, Shoko Ohashi,[...]. Nat Genet 2015
571
23

Cholangiocarcinoma - evolving concepts and therapeutic strategies.
Sumera Rizvi, Shahid A Khan, Christopher L Hallemeier, Robin K Kelley, Gregory J Gores. Nat Rev Clin Oncol 2018
545
22

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
John N Primrose, Richard P Fox, Daniel H Palmer, Hassan Z Malik, Raj Prasad, Darius Mirza, Alan Anthony, Pippa Corrie, Stephen Falk, Meg Finch-Jones,[...]. Lancet Oncol 2019
371
20

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.
Lipika Goyal, Supriya K Saha, Leah Y Liu, Giulia Siravegna, Ignaty Leshchiner, Leanne G Ahronian, Jochen K Lennerz, Phuong Vu, Vikram Deshpande, Avinash Kambadakone,[...]. Cancer Discov 2017
230
19

Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
Apinya Jusakul, Ioana Cutcutache, Chern Han Yong, Jing Quan Lim, Mi Ni Huang, Nisha Padmanabhan, Vishwa Nellore, Sarinya Kongpetch, Alvin Wei Tian Ng, Ley Moy Ng,[...]. Cancer Discov 2017
343
18

TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
Lipika Goyal, Lei Shi, Leah Y Liu, Ferran Fece de la Cruz, Jochen K Lennerz, Srivatsan Raghavan, Ignaty Leschiner, Liudmila Elagina, Giulia Siravegna, Raymond W S Ng,[...]. Cancer Discov 2019
132
18

Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
Maeve A Lowery, Ryan Ptashkin, Emmet Jordan, Michael F Berger, Ahmet Zehir, Marinela Capanu, Nancy E Kemeny, Eileen M O'Reilly, Imane El-Dika, William R Jarnagin,[...]. Clin Cancer Res 2018
171
18

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.
Vivek Subbiah, Ulrik Lassen, Elena Élez, Antoine Italiano, Giuseppe Curigliano, Milind Javle, Filippo de Braud, Gerald W Prager, Richard Greil, Alexander Stein,[...]. Lancet Oncol 2020
91
18

Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.
Angela Lamarca, Jorge Barriuso, Mairéad G McNamara, Juan W Valle. J Hepatol 2020
112
16

Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
Jesus M Banales, Vincenzo Cardinale, Guido Carpino, Marco Marzioni, Jesper B Andersen, Pietro Invernizzi, Guro E Lind, Trine Folseraas, Stuart J Forbes, Laura Fouassier,[...]. Nat Rev Gastroenterol Hepatol 2016
563
15

Cholangiocarcinoma.
Nataliya Razumilava, Gregory J Gores. Lancet 2014
936
15

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.
Rachna T Shroff, Milind M Javle, Lianchun Xiao, Ahmed O Kaseb, Gauri R Varadhachary, Robert A Wolff, Kanwal P S Raghav, Michiko Iwasaki, Peter Masci, Ramesh K Ramanathan,[...]. JAMA Oncol 2019
145
15

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
Yohann Loriot, Andrea Necchi, Se Hoon Park, Jesus Garcia-Donas, Robert Huddart, Earle Burgess, Mark Fleming, Arash Rezazadeh, Begoña Mellado, Sergey Varlamov,[...]. N Engl J Med 2019
431
14

Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
Chaitanya R Churi, Rachna Shroff, Ying Wang, Asif Rashid, HyunSeon C Kang, Jacqueline Weatherly, Mingxin Zuo, Ralph Zinner, David Hong, Funda Meric-Bernstam,[...]. PLoS One 2014
266
14

Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise.
Supriya K Saha, Andrew X Zhu, Charles S Fuchs, Gabriel A Brooks. Oncologist 2016
321
14

New Horizons for Precision Medicine in Biliary Tract Cancers.
Juan W Valle, Angela Lamarca, Lipika Goyal, Jorge Barriuso, Andrew X Zhu. Cancer Discov 2017
237
14

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R Hansen,[...]. J Clin Oncol 2020
664
13

Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Rondell P Graham, Emily G Barr Fritcher, Ekaterina Pestova, John Schulz, Leonid A Sitailo, George Vasmatzis, Stephen J Murphy, Robert R McWilliams, Steven N Hart, Kevin C Halling,[...]. Hum Pathol 2014
163
13

Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.
Yasuhito Arai, Yasushi Totoki, Fumie Hosoda, Tomoki Shirota, Natsuko Hama, Hiromi Nakamura, Hidenori Ojima, Koh Furuta, Kazuaki Shimada, Takuji Okusaka,[...]. Hepatology 2014
276
13

Biliary cancer: Utility of next-generation sequencing for clinical management.
Milind Javle, Tanios Bekaii-Saab, Apurva Jain, Ying Wang, Robin Katie Kelley, Kai Wang, Hyunseon C Kang, Daniel Catenacci, Siraj Ali, Sunil Krishnan,[...]. Cancer 2016
163
13

A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.
Richard D Kim, Vincent Chung, Olatunji B Alese, Bassell F El-Rayes, Daneng Li, Taymeyah E Al-Toubah, Michael J Schell, Jun-Min Zhou, Amit Mahipal, Baek Hui Kim,[...]. JAMA Oncol 2020
110
13

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
13

Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.
Paola Bertuccio, Matteo Malvezzi, Greta Carioli, Dana Hashim, Paolo Boffetta, Hashem B El-Serag, Carlo La Vecchia, Eva Negri. J Hepatol 2019
131
12

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
385
12

Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.
John Bridgewater, Peter R Galle, Shahid A Khan, Josep M Llovet, Joong-Won Park, Tushar Patel, Timothy M Pawlik, Gregory J Gores. J Hepatol 2014
734
12

Identification of targetable FGFR gene fusions in diverse cancers.
Yi-Mi Wu, Fengyun Su, Shanker Kalyana-Sundaram, Nickolay Khazanov, Bushra Ateeq, Xuhong Cao, Robert J Lonigro, Pankaj Vats, Rui Wang, Su-Fang Lin,[...]. Cancer Discov 2013
467
12

Second-line chemotherapy in advanced biliary cancer: a systematic review.
A Lamarca, R A Hubner, W David Ryder, J W Valle. Ann Oncol 2014
180
12

HER2/neu-directed therapy for biliary tract cancer.
Milind Javle, Chaitanya Churi, HyunSeon C Kang, Rachna Shroff, Filip Janku, Rakesh Surapaneni, Mingxin Zuo, Christian Barrera, Humaid Alshamsi, Sunil Krishnan,[...]. J Hematol Oncol 2015
134
11

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.
T Okusaka, K Nakachi, A Fukutomi, N Mizuno, S Ohkawa, A Funakoshi, M Nagino, S Kondo, S Nagaoka, J Funai,[...]. Br J Cancer 2010
423
11

Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib.
Ian M Silverman, Antoine Hollebecque, Luc Friboulet, Sherry Owens, Robert C Newton, Huiling Zhen, Luis Féliz, Camilla Zecchetto, Davide Melisi, Timothy C Burn. Cancer Discov 2021
34
32

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.
Sarina A Piha-Paul, Do-Youn Oh, Makoto Ueno, David Malka, Hyun Cheol Chung, Adnan Nagrial, Robin K Kelley, Willeke Ros, Antoine Italiano, Kazuhiko Nakagawa,[...]. Int J Cancer 2020
97
10

Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J W Valle, I Borbath, S A Khan, F Huguet, T Gruenberger, D Arnold. Ann Oncol 2016
285
10

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.
Teresa Helsten, Sheryl Elkin, Elisa Arthur, Brett N Tomson, Jennifer Carter, Razelle Kurzrock. Clin Cancer Res 2016
317
10

Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy.
Melanie A Krook, Russell Bonneville, Hui-Zi Chen, Julie W Reeser, Michele R Wing, Dorrelyn M Martin, Amy M Smith, Thuy Dao, Eric Samorodnitsky, Anoosha Paruchuri,[...]. Cold Spring Harb Mol Case Stud 2019
36
25

New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
Jeffrey S Ross, Kai Wang, Laurie Gay, Rami Al-Rohil, Janne V Rand, David M Jones, Hwa J Lee, Christine E Sheehan, Geoff A Otto, Gary Palmer,[...]. Oncologist 2014
272
9

Pathogenesis, diagnosis, and management of cholangiocarcinoma.
Sumera Rizvi, Gregory J Gores. Gastroenterology 2013
692
9

Clinical presentation, diagnosis and staging of cholangiocarcinoma.
Alejandro Forner, Gianpaolo Vidili, Marco Rengo, Luis Bujanda, Mariano Ponz-Sarvisé, Angela Lamarca. Liver Int 2019
78
11

Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.
Melanie A Krook, Alexandria Lenyo, Max Wilberding, Hannah Barker, Mikayla Dantuono, Kelly M Bailey, Hui-Zi Chen, Julie W Reeser, Michele R Wing, Jharna Miya,[...]. Mol Cancer Ther 2020
49
18

Pemigatinib: First Approval.
Sheridan M Hoy. Drugs 2020
60
15

Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.
Rachna T Shroff, Erin B Kennedy, Melinda Bachini, Tanios Bekaii-Saab, Christopher Crane, Julien Edeline, Anthony El-Khoueiry, Mary Feng, Matthew H G Katz, John Primrose,[...]. J Clin Oncol 2019
143
9

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.
Rastislav Bahleda, Antoine Italiano, Cinta Hierro, Alain Mita, Andres Cervantes, Nancy Chan, Mark Awad, Emiliano Calvo, Victor Moreno, Ramaswamy Govindan,[...]. Clin Cancer Res 2019
105
9

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Milind Javle, Sameek Roychowdhury, Robin Kate Kelley, Saeed Sadeghi, Teresa Macarulla, Karl Heinz Weiss, Dirk-Thomas Waldschmidt, Lipika Goyal, Ivan Borbath, Anthony El-Khoueiry,[...]. Lancet Gastroenterol Hepatol 2021
17
52

Biliary tract cancer.
Juan W Valle, R Katie Kelley, Bruno Nervi, Do-Youn Oh, Andrew X Zhu. Lancet 2021
80
11

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
Andrew X Zhu, Teresa Macarulla, Milind M Javle, R Kate Kelley, Sam J Lubner, Jorge Adeva, James M Cleary, Daniel V T Catenacci, Mitesh J Borad, John A Bridgewater,[...]. JAMA Oncol 2021
21
42


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.